Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 9/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17321197 | 0.80 | GAA (0.53) | RIPK1 | |
| SCHEMBL18419874 | 0.80 | GAA (0.53) | RIPK1 | |
| SCHEMBL20344576 | 0.75 | RIPK1 (0.36) | RIPK1 | |
| SCHEMBL20049924 | 0.75 | RIPK1 (0.36) | RIPK1 | |
| SCHEMBL18745026 | 0.74 | RIPK1 (0.36) | RIPK1DDB1CRBN | |
| SCHEMBL21307076 | 0.70 | RIPK1 (0.49) | RIPK1 | |
| SCHEMBL22968998 | 0.70 | BRD4 (0.35) | DDB1CRBNL3MBTL1 | |
| SCHEMBL31663492 | 0.69 | CYP19A1 (0.38) | DDB1CRBNL3MBTL1 | |
| SCHEMBL17321226 | 0.69 | CYP19A1 (0.38) | DDB1CRBNL3MBTL1 | |
| SCHEMBL17321196 | 0.67 | GAA (0.54) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | RIPK1 387/4885DDB1 2400/4885CRBN 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.